Drug Profile

R Star 001

Alternative Names: R-Star-001

Latest Information Update: 22 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shenzhen Celconta Life Science
Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

22 Apr 2025 Clinical trials in Unspecified (Parenteral) prior to April 2025 (Shenzhen Celconta Life Science pipeline, April 2025)
31 Jul 2023 CAR T cell therapy - Synkangda Life is available for licensing as of 31 Jul 2023. https://www-xkdbio-com.translate.goog/yjxm?_x_tr_sl=zh-CN&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=sc&_x_tr_sch=http#31
28 Jul 2023 Preclinical trials in Solid tumours in China (Parenteral), prior to July 2023 (Synkangda Life pipeline, July 2023)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com